Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Buried Barrett's metaplasia eradicated after radiofrequency ablation

This month's issue of Endoscopy examines the prevalence of buried Barrett's metaplasia before and after radiofrequency ablation.

News image

Radiofrequency ablation to treat Barrett's esophagus is increasingly accepted.

Description of the etiology, natural history, and prevalence of buried Barrett's metaplasia following radiofrequency ablation is limited, although buried Barrett's metaplasia continues to pose a clinical dilemma.

Dr Yuan and colleagues assessed the prevalence, characteristics, and eradication rate of Barrett's metaplasia in patients with both dysplastic and nondysplastic Barrett's esophagus, treated with radiofrequency ablation and followed over time.

The presence of Barrett's esophagus, dysplasia, and buried Barrett's metaplasia, before and after radiofrequency ablation, was assessed by 2 gastrointestinal pathologists in a retrospective chart review of patients who had undergone radiofrequency ablation, and had completed appropriate follow-up.

The researchers identified 112 patients with completed treatment, and no further planned radiofrequency ablation.

Buried Barrett's metplasia was found in 71% during the radiofrequency ablation treatment
Endoscopy

In 108, no residual Barrett's esophagus was seen after radiofrequency ablation, and 4 patients with persistent Barrett's tissue underwent surgery.

Regarding Barrett's metaplasia, 15% of patients had evidence of buried Barrett's metaplasia during evaluation.

The team found buried Barrett's metplasia in 71% of patients during the radiofrequency ablation treatment.

The research team found that 8 patients had previously undergone non-radiofrequency ablation therapy and radiofrequency ablation for Barrett's esophagus, and 4 having no previous intervention.

In 29%, Barrett's metaplasia was seen only after radiofrequency ablation monotherapy.

The researchers observed that all 17 showed no evidence of buried Barrett's metaplasia at final evaluation, and were classified in the complete remission group.

Dr Yuan's team concluded, "Both Barrett's esophagus and buried Barrett's metaplasia were completely eradicated in all patients with long-term follow-up after radiofrequency ablation."

"Almost half of the patients with buried Barrett's metaplasia had a prior history of non-radiofrequency ablation therapy for Barrett's esophagus compared with 26% the non-Barrett's metaplasia cohort."

"All patients with previously identified Barrett's esophagus, and buried Barrett's metaplasia were completely cleared of disease at final follow-up."

Endoscopy 2012: 44(11): 993-997
23 November 2012

Go to top of page Email this page Email this page to a colleague

 04 March 2015

Advanced search
 04 March 2015 
Progression of Barrett's
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 02 March 2015 
Liver disease in patients awaiting liver transplant
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Prevalence of microscopic colitis
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Thalidomide and refractory Crohn's
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us